1.63 -0.03 (-1.81%)
After hours: 4:46PM EDT
|Bid||1.57 x 4000|
|Ask||1.84 x 2000|
|Day's Range||1.65 - 1.72|
|52 Week Range||1.43 - 6.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Los Angeles-based company said it had a loss of 16 cents per share. The cancer drug developer posted revenue of $100,000 in the period. For the year, the company reported that its loss narrowed to ...
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess CytRx Corporation’s (NASDAQ:CYTR) track record on a highRead More...
On a per-share basis, the Los Angeles-based company said it had a loss of 19 cents. Losses, adjusted for non-recurring gains, were 33 cents per share. The company's shares closed at $1.93. A year ago, ...
CytRx Corporation (NASDAQ:CYTR) is a small-cap stock with a market capitalization of USD $59.70M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
The Los Angeles-based company said it had a loss of 10 cents per share. Losses, adjusted for non-recurring costs, came to 7 cents per share. The company's shares closed at 80 cents. A year ago, they were ...
The American Society of Clinical Oncology, or ASCO, has scheduled its annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The five-day event has Conquer Cancer Foundation as its lead sponsor. ...
On a per-share basis, the Los Angeles-based company said it had a loss of 10 cents. The company's shares closed at 46 cents. A year ago, they were trading at $3.07. _____ This story was generated by Automated ...